Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Farmers Insurance
Moodys
Harvard Business School
Cerilliant
Deloitte
McKinsey
Dow
Covington

Generated: June 25, 2018

DrugPatentWatch Database Preview

Antares Pharma Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ANTARES PHARMA INC, and when can generic versions of ANTARES PHARMA INC drugs launch?

ANTARES PHARMA INC has two approved drugs.

There are thirteen US patents protecting ANTARES PHARMA INC drugs.

There are thirty-four patent family members on ANTARES PHARMA INC drugs in twelve countries.

Summary for Antares Pharma Inc
International Patents:34
US Patents:13
Tradenames:3
Ingredients:2
NDAs:2
Patent Litigation for Antares Pharma Inc: See patent lawsuits for Antares Pharma Inc

Drugs and US Patents for Antares Pharma Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-004 Oct 11, 2013 RX Yes Yes 8,945,063 ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-003 Oct 11, 2013 RX Yes Yes 8,579,865 ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-002 Oct 11, 2013 RX Yes Yes 8,562,564 ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RX Yes Yes 7,744,582 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Antares Pharma Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,428,528 Needle assisted jet injector ➤ Sign Up
9,180,259 Prefilled syringe jet injector ➤ Sign Up
6,565,553 Needle assisted jet injector ➤ Sign Up
9,750,881 Hazardous agent injection system ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Healthtrust
McKesson
Cerilliant
Accenture
Citi
Fish and Richardson
QuintilesIMS
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.